Investigators conducted a multicenter, open-label, Phase II, single-arm study of pembrolizumab in patients with DIPSS intermediate 2 or greater primary, post-essential thrombocythemia or post-polycythemia vera myelofibrosis that were ineligible for or were previously treated with ruxolitinib.
[Blood Advances]
7992332
AAAAAAAA
items
1
apa
0
default
asc
1
167295
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
